GLP-1 Market
LLY $1306.69 ▲ +2.8% NVO $39.43 ▲ +0.9% PFE $30.42 ▲ +1.9% VKTX $25.83 ▼ -2.1% KLRA $13.27 ▲ +2.7% GPCR $21.93 ▼ -0.4% RHHBY $59.62 ▲ +0.9%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

PS1

Company
Pharmasaga Co. Ltd.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
3 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

3 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 23, 2026

Find a Clinical Trial Near Me

See recruiting studies for PS1 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT00869817

    Dominantly Inherited Alzheimer Network (DIAN)

    Washington University School of Medicine 700 participants Est. completion 2031-09 26 sites
    Other conditions: Alzheimer's Disease
    View official trial listing →
  • Recruiting NCT NCT03657732

    The Chinese Familial Alzheimer's Network

    Capital Medical University 40000 participants Est. completion 2038-01-01 65 sites
    Other conditions: Alzheimer Disease, Familial Alzheimer Disease (FAD)
    View official trial listing →
  • Recruiting NCT NCT06996730

    A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease

    Not yet reported, Not yet reported Banner Health 240 participants Est. completion 2030-06-01 1 site
    Other conditions: Autosomal Dominant Alzheimers Disease, Early Onset Alzheimer Disease, Alzheimers Disease
    View official trial listing →
  • Completed NCT NCT01525303

    Effects of Aerobic Exercise Within a Behavioral Treatment Program for Chronic Headaches

    Not yet reported University of Mississippi Medical Center 5 participants Est. completion 2012-08 1 site
    Other conditions: Chronic Headaches
    View official trial listing →
  • Completed NCT NCT01529411

    Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer

    Not yet reported Spanish Oncology Genito-Urinary Group 86 participants Est. completion 2014-12 20 sites
    Other conditions: Carcinoma, Transitional Cell
    View official trial listing →
  • Status unknown NCT NCT01830231

    Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)

    Not yet reported, Not yet reported Associació per a la Recerca Oncologica, Spain 372 participants Est. completion 2016-11 20 sites
    Other conditions: Urothelium Transitional Cell Carcinoma
    View official trial listing →
  • Completed NCT NCT01844947

    Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract

    Not yet reported Dr Anders Ullén 22 participants Est. completion 2018-06-05 3 sites
    Other conditions: Urothelial Carcinoma, Bladder Cancer, Renal Pelvis Cancer, Ureter Cancer, Urethra Cancer
    View official trial listing →
  • Completed NCT NCT01998841

    A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort

    Not yet reported Genentech, Inc. 252 participants Est. completion 2023-08-08 4 sites
    Other conditions: Alzheimer's Disease
    View official trial listing →
  • Completed NCT NCT02669069

    Treatment Evaluation of Neuromodulation for Tinnitus (TENT-A)

    Not yet reported Neuromod Devices Ltd. 326 participants Est. completion 2019-01-30 2 sites
    Other conditions: Tinnitus
    View official trial listing →
  • Terminated NCT NCT02751528

    QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer

    Not yet reported NantBioScience, Inc. 3 participants Est. completion 2018-08-16 2 sites
    Other conditions: Cancer
    View official trial listing →
  • Terminated NCT NCT03127098

    QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

    Not yet reported, Not yet reported NantCell, Inc. 3 participants Est. completion 2017-12-07 1 site
    Other conditions: Thyroid Cancer, Colon Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer
    View official trial listing →
  • Completed NCT NCT03530306

    Treatment Evaluation of Neuromodulation for Tinnitus - Stage A2

    Not yet reported Neuromod Devices Ltd. 191 participants Est. completion 2019-07-18 1 site
    Other conditions: Tinnitus
    View official trial listing →
  • Completed NCT NCT03977584

    Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease

    Not yet reported Hoffmann-La Roche 114 participants Est. completion 2022-04-19 1 site
    Other conditions: Alzheimer Disease
    View official trial listing →
  • Completed NCT NCT04413344

    Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease

    Not yet reported, Not yet reported Kyoto University 8 participants Est. completion 2021-11-24 8 sites
    Other conditions: Familial Alzheimer Disease (FAD), PSEN1 Mutation
    View official trial listing →
  • Completed NCT NCT05176210

    Safety, Pharmacokinetics, and Food Effect of PS1 in Subjects

    Not yet reported Pharmasaga Co. Ltd. 75 participants Est. completion 2026-06-05 1 site Stand-alone
    Other conditions: Type II Diabetes
    View official trial listing →
  • Completed NCT NCT05518682

    Assessment of Bimodal Stimulation Device Compliance and Satisfaction in Individuals With Tinnitus

    Not yet reported University of Minnesota 26 participants Est. completion 2025-02-16 1 site Stand-alone
    Other conditions: Tinnitus
    View official trial listing →
  • Completed NCT NCT05973812

    Safety of Bifidobacterium Breve PS1 for Infants

    Not yet reported Universidad Complutense de Madrid 80 participants Est. completion 2015-03-12 3 sites Stand-alone
    Other conditions: Infant Development, Safety Issues
    View official trial listing →
  • Completed NCT NCT07135986

    Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China

    Not yet reported Sanofi 1602 participants Est. completion 2026-09-24 4 sites
    Other conditions: Meningococcal Infection, Healthy Volunteers
    View official trial listing →
  • Not yet recruiting NCT NCT07689110

    Progressive Pressure Support Reduction as Inspiratory Muscle Endurance Training in Mechanically Ventilated Patients

    Not yet reported University of Santiago de Compostela 60 participants Est. completion 2028-03-30 1 site
    Other conditions: Respiratory Muscle Weakness, Mechanical Ventilation Weaning, Physiotherapy, Endurance Training
    View official trial listing →
  • Not yet recruiting NCT NCT07889505

    A Phase 2 Two-Part Study of Oral PS1 in Healthy Volunteers and Adults With Newly Diagnosed Type 1 Diabetes

    Not yet reported Pharmasaga Co. Ltd. 36 participants Est. completion 2028-10-31 Stand-alone
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.